New Vial Size Approved for CSL Behring’s Hizentra
- By BSTQ Staff
The U.S. Food and Drug Administration has approved a 10 g (50 mL) vial size for Hizentra, immune globulin subcutaneous (human), manufactured by CSL Behring. Hizentra is the only 20 percent subcutaneous immune globulin therapy, which keeps serum immunoglobulin G (IgG) levels consistent week to week to help protect people with primary immunodeficiency against infections. The new vial size, which became available in the U.S. in October, will reduce the number of vials that patients must use when higher doses are required, thus increasing administration efficiency and reducing complexity of care. In addition to the 10 g vial, Hizentra is also available in 1 g (5 mL), 2 g (10 mL) and 4 g (20 mL) vials.
“CSL Behring remains dedicated to providing every patient with options that will enhance his or her treatment experience,” said Lynne Powell, senior vice president, North America Commercial Operations. “The availability of Hizentra in a 10 g vial will reduce vial preparation for infusion, therefore saving time for both patients and their caregivers.”
